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Purpose: While cardiac troponins (C-Tn) are widely used in the emer-
gency room in case of chest pain, there is an increasing rate of prescription of
this test by general practitioners (GPs) in outpatients. Limited data are avai-
lable on the motivations and the issue of C-Tn requested by GPs. We sought
to assess the reasons for C-Tn test prescribed by GPs in our community in
France, and the management of the positive cases.
Methods: We retrospectively retrieved all the C-Tn test requests made by GPs
to the 2 major laboratories in our community of 250,000 inhabitants, within a
period of 4 months. The GPs were contacted by phone to assess their motivations.
Results: During this period, 306 C-Tn tests were requested by 157 GPs.
We excluded 64 cases because of insufficient data. They were comparable to
those included in the study in terms of age, gender, and positive test rates.
Among the 242 cases studied (median age 70 years, 51% males), 41% had ≥3
coronary risk factors. C-Tn was requested because of chest pain in
202 patients (83%). 71% had atypical pain. The prescription was made in
more than 6 and 24 hours after symptom’s onset in 78% and 55% of cases,
respectively. ECG was performed before C-Tn test prescription in only 15%
of cases. In 92% of cases, C-Tn test was negative. Among the 18 positive
cases, 5 (19%) remained at home (3 very old patients, mean age 91 years, and
2 cases considered as false positives). Among the 13 remaining positive cases,
7 were referred directly to cardiologists and 6 to an emergency department.
Among these 13 patients, 11 were referred without medical transportation.
Only 1 patient was transferred medically directly to the cath lab, 24 hours
after chest pain onset.
Conclusion: Cardiac troponin is mainly requested by GPs to exclude acute
coronary syndrome in case of atypical chest pain with delayed consultation.
However, the positivity of this test was useless in 1 out of 5 patients since it
has not changed their management. While in the majority, the C-Tn tests
requested by GPs are negative and avoid hospitalization, the management of
patients with positive test is delayed and not secured. 
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Purpose: Serum Iron (I) is a cofactor of several enzymes, but also, a mediator
of reactive oxygen species production. In literature, the impact of I on prognosis
of patients (P) with Acute Coronary Syndromes (ACS) is not well established.
Methods: Prospective study including 228 P with ACS consecutively
admitted to a coronary care unit over 6 months. P were excluded if they:
didn’t have I measurement (n=26); were under I/erythropoietin supplementa-
tion (n=0); had chronic inflammatory disease (n=8) or malignancy (n=7). 
Results: Pin the lowest Q had higher prevalence of moderate to severe val-
vular disease (10,2% vs 2,2% vs 0%vs 0%; p=0,012) and less frequently pre-
sented with Unstable Angina (0% vs 0% vs 4,3% vs 17,4%; p<0,001). At
admission, they had more often anemia (80,4% vs 58,7% vs 48,8% vs 43,5%;
p=0,014) and signs of heart failure (28,3% vs 24% vs 8,9% vs 8,7%; p=0,004).
They had lower mean corpuscular hemoglobin levels (30,1±2,6 vs 30,7±1,5
vs 30,8±1,5 vs 31,9±3,3g/dL; p=0,002) and higher mean levels of RDW
(13,9±1,3 vs 13,6±1 vs 13,4±1 vs 13,2±0,7%; p=0,008), C reactive protein
(31,7±3856 vs 2199±2769 vs 2137±2550 vs 1167±1900pg/mL; p=0,022).
They had more frequently moderate to severe left ventricular systolic dysfunc-
tion (41,3% vs 28,3% vs 17,4% vs 17,4%; p=0,035). During hospitalization,
2 P died, and we verified a non-significant trend to higher in-hospital mor-
tality in P in the lowest Q (2% vs 2% vs 0% vs 0%). 
The incidence of MACE was significantly higher in the lowest Q (41,7%
vs 31% vs 17,4% vs 10,9%; p=0,002). After multivariate logistic regression,
inclusion of P in the lowest Q persisted as an independent predictor of in-
hospital MACE (OR 4,2; 95% CI 1,27 – 4,45; p=0,019).
Conclusion: Despite the small size of study population, our findings sug-
gest that I may be an independent predictor of in-hospital MACE, with the
lowest I associated with a worse prognosis. A possible trend to increased mor-
tality in this group should be clarified in future studies.
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Background: Risk stratification is a key element to treatment optimization
and prognostic assessment in acute coronary syndromes (ACS). The aim of
the present study was to evaluate and compare the predictive power (PP) of
6 month mortality (6M) of different complete blood count parameters in
patients (P) with ACS.
Methods: Retrospective study including P with ACS consecutively
admitted to a coronary care unit over 4 years and a minimal 6 month follow-
up. In all P the following CBC parameters were evaluated in the first 24 hours:
hemoglobin (Hg), hematocrit (Htc), red blood cell distribution width (RDW)
and platelets (Pl). In a subgroup of 540 P admitted over a 1 year, mean cor-
puscular volume (MCV), mean corpuscular hemoglobin (MCH), leukocytes
(L) and neutrophils (N) were also evaluated.
Results: We included 1906 P (mean age 64±13y; 49,9% with ST-elevation
infarction). The in-hospital mortality was 3,9% and 6M was 8,9%. After cal-
culation of 6M AUC, only Hg (0,712; p<0,001), Htc (0,703; p<0,001) and
RDW (0,622; p=0,05) had PP of 6M. There were no statistically significant
differences between the PP of Hg, Hct and RDW. From the cut-off values
obtained, a multivariate logistic regression model was constructed. Only Hct
and RDW persisted as independent predictors of 6M, with an OR of 3,6 (CI
95%; 2,18-40,43; p<0,001) and 2,8 (CI 95%; 1,04-7,67; p=0,04), respectively.
In a subgroup of P, in addition to previous parameters, L (0,598; p=0,04) and
N (0,619; p=0,014) also had PP of 6M. There were no statistically significant
differences between the PP of Hg, Hct, RDW, L and N, with the exception of
RDW that had a stronger PP than L (p=0.032). After multivariate analysis,
L and N also persisted as independent predictors of 6M, with an OR of 5,1 (CI
95%; 1,42-18,18; p=0,012) and 3,0 (CI 95%; 1,04-8,74; p=0,04), respectively. 
Conclusion: CBC is a routine blood test, which includes parameters that
without extra costs can be helpful in risk stratification of ACS. In the present
study, Hg, Hct, RDW, L and N had PP for 6M in ACS. There were no signi-
ficant differences regarding the PP of 6M between these variables, with the
exception of RWD that had a stronger PP than L.
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Purpose: Stroke is a serious complication after acute myocardial infarc-
tion (AMI) and is associated with an increased risk of death. However, the
increased use of evidence-based therapies (ASA, P2Y12 and statins) has
reduced the risk of stroke during the last decade. Whereas the
pathophysiological mechanisms are not exactly known, increased inflamma-
